US 12,377,047 B2
Emulsions for treating mucous membrane infections
Marion Noe, Vienna (AT); and Christian R. Noe, Vienna (AT)
Assigned to ProFem GmbH, Vienna (AT)
Filed by ProFem GmbH, Vienna (AT)
Filed on Aug. 14, 2023, as Appl. No. 18/233,560.
Application 18/233,560 is a continuation of application No. 16/763,372, granted, now 11,779,538, previously published as PCT/EP2018/081253, filed on Nov. 14, 2018.
Claims priority of application No. 17201650 (EP), filed on Nov. 14, 2017; and application No. 17201651 (EP), filed on Nov. 14, 2017.
Prior Publication US 2023/0414505 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/107 (2006.01); A61K 9/10 (2006.01); A61K 31/196 (2006.01); A61K 31/4174 (2006.01); A61K 47/22 (2006.01); A61P 15/02 (2006.01); A61P 31/04 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 45/06 (2006.01)
CPC A61K 9/107 (2013.01) [A61K 9/10 (2013.01); A61K 31/196 (2013.01); A61K 31/4174 (2013.01); A61K 47/22 (2013.01); A61P 15/02 (2018.01); A61P 31/04 (2018.01); A61K 9/0014 (2013.01); A61K 9/0034 (2013.01); A61K 9/06 (2013.01); A61K 45/06 (2013.01)] 18 Claims
 
1. An emulsion with an aqueous phase and an oil phase, containing an NSAID, wherein
(a) the NSAID is diclofenac in a concentration of 0.1 to 0.5 weight percent, indometacin in a concentration of 0.1 to 0.4 weight percent, naproxen in a concentration of 1 to 5 weight percent, ibuprofen in a concentration of 0.5 to 2.5 weight percent, dexibuprofen in a concentration of 0.25 to 1.25 weight percent, ketoprofen in a concentration of 0.25 to 1.25 weight percent, mefenamic acid in a concentration of 0.5 to 4 weight percent, or lornoxicam in a concentration of 0.02 to 0.04 weight percent,
(b) a weight ratio of the water phase to the oil phase in this emulsion is between the values 2.0 and 2.7, and
(c) a pH value of the emulsion is not less than the value 6.5 and not more than 8.5.